Trending Industry Today: GIANT BIOGENE Leads Gains In Aesthetic Medicine Stocks

Moomoo NewsSep 30 03:40 ET

Founder Securities: Comprehensive policy efforts, focus on pro-cyclical sectors

Main theme of beauty and skincare: Policies are fully implemented, and the beauty and skincare sector is expected to benefit first.

Zhitong FinanceSep 29 18:34 ET

GIANT BIOGENE: INTERIM REPORT 2024

HKEXSep 26 04:46 ET · Announcements

[Brokerage Focus] Tianfeng Securities maintains a 'buy' rating on Juzi Biotech (02367), citing its impressive performance in the first half of the year and rapid growth in new product sales.

Jingu Finance News | Tianfeng Securities released research pointing out that Juzi Biotech (02367) achieved revenue of 2.54 billion yuan in the first half of the year, a year-on-year increase of 58.2%; achieved a net income of 0.98 billion yuan, a year-on-year increase of 47.4%. The bank indicated that in terms of products, the functional skincare products of the company in 2024H1 achieved revenue of 1.94 billion yuan, a year-on-year increase of 62%, accounting for 76.4% of total revenue; medical dressings revenue was 0.59 billion yuan, a year-on-year increase of 48.9%, accounting for 23.3% of total revenue; revenue from health food and other products was 0.009 billion yuan, a year-on-year decrease of 21.1%, accounting for 0.3% of total revenue.

Golden Guardian Financial NewsSep 25 03:33 ET

Hong Kong stock market anomaly | Juzi Bio (02367) rose more than 5%, recently received a patent authorization for the invention of type XVII collagen by the restructuring personnel.

Juzi Biotech (02367) rose more than 5%, as of the time of writing, rose 5.17%, reported HKD 37.6, with a turnover of HKD 0.141 billion.

Zhitong FinanceSep 19 02:57 ET

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Largest Shareholder, Chief Scientific Officer Daidi Fan Sees Holdings Value Fall by 8.6% Following Recent Drop

Simply Wall StSep 15 20:32 ET